Aptose Presents New Preclinical CG-806 Data at the 2019 ASH Annual Meeting
09 déc. 2019 11h00 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting...
Aptose Presents Highlights From Corporate Event At ASH
07 déc. 2019 11h00 HE
|
Aptose Biosciences, Inc.
SAN DIEGO, TORONTO and ORLANDO, Fla., Dec. 07, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) released highlights from a corporate event and clinical update today held at...
Aptose Appoints Rafael Bejar, M.D., Ph.D., as Chief Medical Officer
04 déc. 2019 07h30 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the...
Aptose to Present at 31st Annual Piper Jaffray Healthcare Conference
02 déc. 2019 07h30 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...
Aptose to Present at BIO-Europe Conference
07 nov. 2019 07h30 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...
Aptose to Present New CG-806 Data at the 2019 ASH Annual Meeting
06 nov. 2019 09h54 HE
|
Aptose Biosciences, Inc.
– Company to Hold Event During ASH – – CG-806 Preclinical Abstracts Accepted for Presentation – SAN DIEGO and TORONTO, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”)...
Aptose Reports Results for the Third Quarter Ended September 30, 2019
05 nov. 2019 16h02 HE
|
Aptose Biosciences, Inc.
CG-806 Mutation Agnostic FLT3/BTK Inhibitor and APTO-253 MYC Inhibitor Safely Dose Escalate CLL Patient Treated with Second Dose Level of CG-806 Shows Evidence of Clinical Response Conference Call...
Aptose To Release Third Quarter Ended September 30, 2019 Financial Results and Hold Conference Call on November 5, 2019
22 oct. 2019 07h00 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Oct. 22, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage biotechnology company developing first-in-class agents that target the...